Jafron Biomedical Co.,Ltd.
Shenzhen Stock ExchangeTotal Valuation
Jafron Biomedical Co.,Ltd. carries a market capitalization of 13.31B, placing it among publicly traded companies globally. Its enterprise value stands at 16.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.31B |
| Enterprise Value | 16.91B |
Share Statistics
Jafron Biomedical Co.,Ltd. currently has 798.61M shares outstanding.
| Shares Outstanding | 798.61M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jafron Biomedical Co.,Ltd. trades at a trailing price-to-earnings ratio of 26.93. The price-to-sales ratio is 7.64, and the price-to-book ratio stands at 5.74.
| PE Ratio | 26.93 |
| PS Ratio | 7.64 |
| PB Ratio | 5.74 |
| P/TBV Ratio | 5.87 |
| P/FCF Ratio | 90.40 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jafron Biomedical Co.,Ltd. trades at an EV/EBITDA multiple of 20.05 and an EV/FCF ratio of 69.72. The EV/Sales ratio of 7.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.05 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.30 |
| EV / EBITDA | 20.05 |
| EV / EBIT | 20.05 |
| EV / FCF | 69.72 |
Financial Position
Jafron Biomedical Co.,Ltd. maintains a current ratio of 3.56, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.80, indicating elevated leverage, while an interest coverage ratio of 14.55 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.56 |
| Quick Ratio | 2.96 |
| Debt / Equity | 44.80 |
| Debt / EBITDA | 1.66 |
| Interest Coverage | 14.55 |
Financial Efficiency
Jafron Biomedical Co.,Ltd. posts a return on equity of 21.42 and a return on invested capital of 14.41.
| Return on Equity (ROE) | 21.42 |
| Return on Assets (ROA) | 12.26 |
| Return on Invested Capital (ROIC) | 14.41 |
| Return on Capital Employed (ROCE) | 15.41 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.40 |
Taxes
Over the trailing twelve months, Jafron Biomedical Co.,Ltd. has paid 156.52M in income taxes, reflecting an effective tax rate of 19.36.
| Income Tax | 156.52M |
| Effective Tax Rate | 19.36 |
Stock Price Statistics
Jafron Biomedical Co.,Ltd.'s stock has declined approximately -27.01401% over the past 52 weeks. The 50-day moving average sits at 17.74, while the 200-day moving average is 19.40.
| Beta (5Y) | N/A |
| 52-Week Price Change | -27.01401% |
| 50-Day Moving Average | 17.74 |
| 200-Day Moving Average | 19.40 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jafron Biomedical Co.,Ltd. generated 2.32B in revenue and converted that into 657.41M in net income, yielding earnings per share of 0.79. EBITDA reached 843.58M, while operating income came in at 843.58M.
| Revenue | 2.32B |
| Gross Profit | 1.86B |
| Operating Income | 843.58M |
| Pretax Income | 808.62M |
| Net Income | 657.41M |
| EBITDA | 843.58M |
| EBIT | 843.58M |
| Earnings Per Share (EPS) | 0.79 |
Balance Sheet
Jafron Biomedical Co.,Ltd. holds 2.19B in cash and equivalents against 1.40B in total debt, resulting in a net debt position of 447.68M. Total book value stands at 3.08B, with working capital of 1.89B providing operational flexibility.
| Cash & Cash Equivalents | 2.19B |
| Total Debt | 1.40B |
| Net Debt | 447.68M |
| Equity (Book Value) | 3.08B |
| Book Value Per Share | 3.76 |
| Working Capital | 1.89B |
Cash Flow
After subtracting -195.86M in capital expenditures, free cash flow totaled -195.86M - equivalent to -0.24 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -195.86M |
| Free Cash Flow | -195.86M |
| FCF Per Share | -0.24 |
Margins
Jafron Biomedical Co.,Ltd. operates with a gross margin of 80.47, reflecting its pricing power and cost economics. The operating margin of 36.42 and net profit margin of 28.38 provide insight into operational efficiency.
| Gross Margin | 80.47 |
| Operating Margin | 36.42 |
| Pretax Margin | 34.91 |
| Profit Margin | 28.38 |
| EBITDA Margin | 36.42 |
Dividends & Yields
The company's payout ratio of 100.33 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.79 |
| Dividend Yield | N/A |
| Payout Ratio | 100.33 |
| Shareholder Yield | 5.48 |
| FCF Yield | 1.11 |
Stock Splits
Jafron Biomedical Co.,Ltd.'s most recent stock split took place on May 20, 2020 with a 10:19 split ratio.
| Last Split Date | 5/20/2020 |
| Split Ratio | 10:19 |
Scores
Jafron Biomedical Co.,Ltd. posts an Altman Z-Score of 7.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.00 |